---
title: "Dupixent (dupilumab) in atopic dermatitis: Dosing and administration questions"
description: "Dosing and administration questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Administration, Treatment combinations, and Treatment duration. Questions: What is the Dupixent dosage for adults with atopic dermatitis? What is the Dupixent dose for children aged 6 to 17 with atopic dermatitis? What is the Dupixent dose for children aged 6 months to 5 years with atopic dermatitis? Does Dupixent need a loading dose for atopic dermatitis? 7 further questions follow. 11 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Dosing and administration questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## Dosing

<a id="dupixent-adult-dose"></a>

### What is the Dupixent dosage for adults with atopic dermatitis?

> “18+ years
>
> One dosage regimen, regardless of weight
>
> INITIAL LOADING DOSE
>
> 600 mg
>
> (2 x 300 mg)
>
> FOLLOWED BY
>
> 300 mg Q2W
>
> (1 x 300 mg)”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=18%2B%20years,%281%20x%20300%20mg%29)

> “The recommended dosage of DUPIXENT for adult patients is an initial dose of 600 mg (two 
> 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 6, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=6)

<a id="dupixent-pediatric-dose"></a>

### What is the Dupixent dose for children aged 6 to 17 with atopic dermatitis?

> “Table 2: 
> Dosage of DUPIXENT in Pediatric Patients 6 Years to 17 Years of Age with 
> Atopic Dermatitis 
> Body Weight 
> Initial Loading Dose 
> Subsequent Dosage 
> 15 to less than 30 kg 
> 600 mg (two 300 mg injections) 
> 300 mg every 4 weeks (Q4W) 
> 30 to less than 60 kg 
> 400 mg (two 200 mg injections) 
> 200 mg every 2 weeks (Q2W) 
> 60 kg or more 
> 600 mg (two 300 mg injections) 
> 300 mg every 2 weeks (Q2W)”

Source: [DUPIXENT: dupixent_fpi.pdf, page 6, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=6)

> “5 kg is equal to 11 lb; 15 kg is equal to 33 lb; 30 kg is equal to 66 lb; 60 kg is equal to 132 lb.”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=5%20kg%20is%20equal%20to,is%20equal%20to%20132%20lb.)

<a id="dupixent-infant-dose"></a>

### What is the Dupixent dose for children aged 6 months to 5 years with atopic dermatitis?

> “Table 1: 
> Dosage of DUPIXENT in Pediatric Patients 6 Months to 5 Years of Age with 
> Atopic Dermatitis 
> Body Weight 
>  Recommended Dosage<sup>a</sup> 
> 5 to less than 15 kg 
> 200 mg (one 200 mg injection) every 4 weeks (Q4W) 
> 15 to less than 30 kg 
> 300 mg (one 300 mg injection) every 4 weeks (Q4W) 
> <sup>a</sup> For pediatric patients 6 months to 5 years of age with AD, no initial loading dose is recommended.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 6, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=6)

> “5 kg is equal to 11 lb; 15 kg is equal to 33 lb; 30 kg is equal to 66 lb; 60 kg is equal to 132 lb.”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=5%20kg%20is%20equal%20to,is%20equal%20to%20132%20lb.)

<a id="dupixent-loading-dose"></a>

### Does Dupixent need a loading dose for atopic dermatitis?

> “DUPIXENT offers at-home and in-office administration options. DUPIXENT is administered as a subcutaneous injection twice a month or monthly (depending on age and weight) after an initial loading dose (in patients aged 6+ years). In patients aged 6 months to 5 years, no initial loading dose is recommended.<sup>1</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=DUPIXENT%20offers%20at%2Dhome%20and%20in%2Doffice,no%20initial%20loading%20dose%20is)

On the page, select: How is DUPIXENT administered?

> “For patients with AD, asthma, PN, CSU, and BP taking an initial 600 mg dose, administer each 
> of the two DUPIXENT 300 mg injections at different injection sites. 
> For patients with AD, asthma, and CSU taking an initial 400 mg dose, administer each of the two 
> DUPIXENT 200 mg injections at different injection sites.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 5, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=5)

<a id="dupixent-missed-dose"></a>

### What should be done if a dose of Dupixent is missed?

> “If an every 2 week dose is missed, administer the injection within 7 days from the missed dose 
> and then resume the patient’s original schedule. If the missed dose is not administered within 7 
> days, administer the dose, starting a new schedule based on this date. 
> If an every 4 week dose is missed, administer the injection within 7 days from the missed dose 
> and then resume the patient’s original schedule. If the missed dose is not administered within 7 
> days, administer the dose, starting a new schedule based on this date.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 9, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=9)

## Administration

<a id="dupixent-injection-technique"></a>

### How and where is Dupixent injected?

> “Preparation and administration of DUPIXENT
> Patients and/or caregivers should read the Instructions for Use prior to injecting
> Instruct patients and/or caregivers to administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
> The upper arm can also be used if a caregiver administers the injection
> It is important to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred
> For the initial dose, patients and/or caregivers should administer each DUPIXENT injection at a different injection site
> In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver. In children 12 years of age and older, it is recommended that DUPIXENT be administered by or under the supervision of an adult”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=Patients%20and%2For%20caregivers%20should%20read%20the,the%20supervision%20of%20an%20adult)

<a id="dupixent-self-injection-age"></a>

### At what age can patients self-inject Dupixent?

> “A caregiver or patient 12 years of age and older may inject DUPIXENT using the pre-filled 
> syringe or pre-filled pen. In pediatric patients 12 years of age and older, administer DUPIXENT 
> under the supervision of an adult. In pediatric patients 6 months to less than 12 years of age, 
> administer DUPIXENT by a caregiver.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 5, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=5)

> “A patient may self-inject DUPIXENT—or a caregiver may administer DUPIXENT—after training has been provided by a healthcare provider on proper subcutaneous injection technique using the pre-filled syringe or pre-filled pen<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=A%20patient%20may%20self%2Dinject%20DUPIXENT%E2%80%94or,the%20pre%2Dfilled%20syringe%20or%20pre%2Dfilled)

> “In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver
> In children 12 years of age and older, it is recommended that DUPIXENT be administered by or under the supervision of an adult”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=In%20children%206%20months%20to,the%20supervision%20of%20an%20adult)

<a id="dupixent-pen-syringe"></a>

### What forms and strengths does Dupixent come in?

> “Available in a 200 mg and 300 mg pre-filled pen (for indicated patients 2+ years of age) or pre-filled syringe (for indicated patients 6+ months of age) for subcutaneous injection<sup>1,2</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=Available%20in%20a%20200%20mg,months%20of%20age%29%20for%20subcutaneous)

> “DUPIXENT is a clear to slightly opalescent, colorless to pale yellow solution available as:
>
> Injection: 300 mg/2 mL in a single-dose, pre-filled pen with hidden needle or syringe with needle shield
> Injection: 200 mg/1.14 mL in a single-dose, pre-filled pen with hidden needle or syringe with needle shield”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=DUPIXENT%20is%20a%20clear%20to,pre%2Dfilled%20pen%20with%20hidden%20needle%20or%20syringe%20with%20needle%20shield)

On the page, select: Dosage forms and strengths

> “DUPIXENT is available in cartons containing 2 pre-filled pens or syringes with needle shields. Each 300 mg pre-filled syringe or pre-filled pen delivers
> 300 mg/2 mL. Each 200 mg pre-filled syringe or pre-filled pen delivers 200 mg/1.14 mL.”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=DUPIXENT%20is%20available%20in%20cartons,pen%20delivers%20200%20mg%2F1.14%20mL.)

On the page, select: How it’s supplied

<a id="dupixent-room-temperature"></a>

### How long should Dupixent warm to room temperature before injection?

> “Before injection, instruct patients and/or caregivers to remove the DUPIXENT pre-filled pen or syringe from the refrigerator and allow DUPIXENT to reach room temperature without removing the needle cap.
>
> 45 minutes for the 300 mg/2 mL
> pre-filled pen or syringe
> 30 minutes for the 200 mg/1.14 mL
> pre-filled pen or syringe
>
> Patients and/or caregivers should not use the pre-filled pen or syringe if the liquid contains visible particulate matter, or is discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow).
>
> Patients and/or caregivers should discard any unused product remaining in the pre-filled pen or syringe in accordance with local requirements.”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=Before%20injection%2C%20instruct%20patients%20and%2For,in%20accordance%20with%20local%20requirements.)

On the page, select: Preparation for use

## Treatment combinations

<a id="dupixent-topical-therapies"></a>

### Can Dupixent be used with topical corticosteroids or topical calcineurin inhibitors?

> “No, the use of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) is not required with DUPIXENT.
>
> DUPIXENT can be used with or without TCS<sup>1</sup>
> DUPIXENT can be used concomitantly with TCIs, but should be reserved for problem areas only, such as the face, neck, and intertriginous and genital areas<sup>1</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=No%2C%20the%20use%20of%20topical,neck%2C%20and%20intertriginous%20and%20genital)

On the page, select: Does DUPIXENT have to be used with concomitant topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)?

> “Concomitant Topical Therapies 
> DUPIXENT can be used with or without topical corticosteroids. Topical calcineurin inhibitors 
> may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous 
> and genital areas.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 6, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=6)

## Treatment duration

<a id="dupixent-treatment-duration"></a>

### How long do patients need to stay on Dupixent for atopic dermatitis?

> “Each patient may respond differently to DUPIXENT. Use clinical judgment to determine how long a patient should remain on DUPIXENT.”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=Each%20patient%20may%20respond%20differently,patient%20should%20remain%20on%20DUPIXENT.)

On the page, select: How long do atopic dermatitis patients need to remain on therapy with DUPIXENT?

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Indication](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
